Cellectis S.A.
CLLS · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $42 | $1 | $19 | $30 |
| % Growth | 5,397.5% | -96.1% | -36.8% | – |
| Cost of Goods Sold | $9 | $7 | $8 | $2 |
| Gross Profit | $32 | -$7 | $11 | $29 |
| % Margin | 77.9% | -882.6% | 55.7% | 93.9% |
| R&D Expenses | $91 | $88 | $98 | $118 |
| G&A Expenses | $8 | $8 | $9 | $38 |
| SG&A Expenses | $8 | $8 | $9 | $23 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $3 |
| Other Operating Expenses | -$7 | -$5 | -$6 | -$9 |
| Operating Expenses | $92 | $91 | $100 | $132 |
| Operating Income | -$60 | -$97 | -$90 | -$103 |
| % Margin | -143.5% | -12,887.7% | -467.7% | -341% |
| Other Income/Exp. Net | $23 | -$19 | -$9 | $7 |
| Pre-Tax Income | -$37 | -$116 | -$99 | -$97 |
| Tax Expense | $0 | $0 | $0 | -$0 |
| Net Income | -$37 | -$101 | -$106 | -$114 |
| % Margin | -88.6% | -13,385.3% | -553.6% | -376.3% |
| EPS | -0.41 | -1.77 | -2.33 | -1.93 |
| % Growth | 76.8% | 24% | -20.7% | – |
| EPS Diluted | -0.41 | -1.77 | -2.33 | -1.93 |
| Weighted Avg Shares Out | 91 | 57 | 46 | 45 |
| Weighted Avg Shares Out Dil | 91 | 57 | 46 | 45 |
| Supplemental Information | – | – | – | – |
| Interest Income | $11 | $4 | $1 | $1 |
| Interest Expense | $7 | $5 | $4 | $4 |
| Depreciation & Amortization | $20 | $19 | $18 | $14 |
| EBITDA | -$9 | -$93 | -$76 | -$78 |
| % Margin | -22.8% | -12,269.8% | -398.4% | -258.4% |